Biotechnology firm Crucell on Tuesday announced it has booked its first ever positive result with net profit of €12.3m in the third quarter of this year, compared with a loss of €4.5m in the year-earlier period.

Crucell’s sales rose 321% to €82m on the sale of children’s vaccines and income from licences. The firm has raised its full-year growth forecast to between 25% and 30%.

For the full Crucell statement, click here